HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)
HeartSciences, a medical device company leading innovation in electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today the results of a clinical study serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New York, NY and the West Virginia University (WVU) Heart and Vascular Institute, Morgantown, WV. The results were provided at onlineJACC.org, April 09, 2018 and will be published in the April 17, 2018 issue of Journal of the American College of Cardiology (JACC), a peer-reviewed journal in cardiovascular medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410005607/en/
HeartSciences’ MyoVista wavECG Device with Informatics (Photo: Business Wire)
The article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presents the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista ® Wavelet ECG (wavECGTM) as a diagnostic tool for predicting myocardial relaxation abnormalities. Abnormal relaxation is an early feature of many types of heart disease and a key characteristic of left ventricular diastolic dysfunction (LVDD). It is typically detected using echocardiographic imaging. LVDD is a strong predictor of cardiovascular and all-cause mortality.1 Ischemia, hypertension, diabetes, valvular disease and reduced systolic function are all associated with LVDD.1, 2
Results from the feasibility study demonstrate MyoVista patented technology can detect myocardial relaxation abnormalities associated with LVDD. The study results demonstrated 80% sensitivity and 84% specificity with an area under the curve of 91% for the prediction of low (e’), an echocardiographic parameter widely used in determination of LVDD. Prediction of low (e’) also correctly identified 23 out of 28 study subjects (82%) with significant underlying coronary artery disease. Additionally, MyoVista wavECG prediction of relaxation abnormalities also allowed recognition of subjects with more advanced stages of DD and concurrent CAD with significantly more incremental value compared with clinical variables and conventional ECG information. The feasibility study was performed using machine learning analysis often described as artificial intelligence or AI. The study included a limited number of patients as well as other limitations and future studies were recommended to address these limitations.
Conclusions of the trial suggest a potential role for the MyoVista wavECG Device as a screening tool for patients at risk for LVDD that would benefit from echocardiographic evaluations.
Partho Sengupta, MD, Professor, Chief of Cardiology and Chair of Cardiac Innovation, WVU Heart & Vascular Institute and Principal Investigator in the study, commented, “These data are extremely encouraging as they suggest a potential role of signal processed ECG in early cardiac disease detection. It is quite remarkable that MyoVista demonstrated a high diagnostic precision in detecting a state of cardiac muscle dysfunction only previously detectable using cardiac ultrasound techniques. This can eventually help in appropriate cardiac testing and reduce overall healthcare costs.”
"These positive results demonstrate that MyoVista wavECG Technology, which includes our patented signal processing methods combined with artificial intelligence, can lead to enhanced capabilities and completely new uses for electrocardiography-based (ECG) devices,” stated Mark Hilz, President and CEO of HeartSciences.
Andrew Simpson, Chairman of HeartSciences, stated, “This study of MyoVista wavelet ECG technology is a significant step towards enhancing the most commonly used low-cost, front-line tool, the 12-lead resting ECG, with new capabilities that can provide more effective risk stratification related to the early detection of heart disease.”
A total of 188 subjects referred from outpatient clinics to the Icahn School of Medicine, Mount Sinai Hospital for coronary computed tomography (CT) angiography also undertook in the same visit, comprehensive two-dimensional echocardiography (including tissue Doppler) that included assessment of LVDD. Subjects with arrhythmias, unstable angina, previous cardiac surgery, a pacemaker, chest deformity, or an inability to express well-defined mitral annular velocities due to severe mitral annular calcifications were excluded. Additional analysis was conducted related to a comparison cohort that were evaluated at WVU, Heart and Vascular Institute which further validated MyoVista wavECG healthy patient characteristics as well as age and population distribution information.
1. LV Diastolic Dysfunction and Prognosis, Dalane W. Kitzman, et al., Circulation, 2012 February 14: 125(6): 743-745. doi:10.1161.CIRCULATIONAHA.111.086843
2. Diastolic Dysfunction and Diastolic Heart Failure: Diagnostic, Prognostic and Therapeutic Aspects, Maurizio Galderisi, Cardiovascular Ultrasound, 2005, 3-9 doi:10.1186/1476-7120-3-9
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Device is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently available for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Gemalto First Quarter 2018 Revenue26.4.2018 22:00 | Pressemelding
Regulatory News: Gemalto (Euronext NL0000400653 - GTO), the world leader in digital security today announces its revenue for the first quarter of 2018. Revenue (€ in millions) First quarter 2018 First quarter 2017 Change at constant exchange rates Change at historical exchange rates Identity, IoT & Cybersecurity 293 256 +24% +15% Smartcards & Issuance 357 396 (2%) (10%) Total 650 651 +8% = Philippe Vallée, Chief Executive Officer, commented: “Gemalto grew well this quarter driven by a solid increase in the Identity, IoT & Cybersecurity segment that more than offset the anticipated revenue decrease in the Smartcards & Issuance segment. During the quarter, commercial synergies with the newly acquired Identity Management business began to kick in and resulted in milestone wins in Governments. Gemalto also announced the launch of two ground-breaking laser-personalized innovations designed to significantly increase the security of passports and IDs. The Cybersecurity business grew well in E
Elliott Advisors (UK) Limited Statement on Telecom Italia26.4.2018 19:49 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”) today sent a new letter and a presentation to Telecom Italia (“TIM” or the “Company”) shareholders calling upon shareholders to uphold best practice governance principles at TIM’s upcoming shareholder meeting on May 4th. Inadequate governance and poor stewardship have imposed a heavy cost on TIM’s stakeholders for too long. Vivendi’s repeated missteps and self-serving behaviour have eroded the value of TIM’s shares and destroyed shareholder trust. The question being put to TIM shareholders on May 4th is: can you entrust your investment to Vivendi as long-term stewards of your capital and this company moving forward? Shareholders should take the opportunity to correct a governance structure rife with conflict and demand high quality and independent stewardship at the Board level. Shareholders have the opportunity to remove an otherwise permanent, persisting and pervasive impairment of value. This pivotal vote offers a textbook opportunity to put
Javier Gómez Noya Chooses ROKA Eyewear26.4.2018 18:15 | Pressemelding
ROKA, the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya, expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/ Javier Gómez Noya Chooses ROKA Eyewear (Photo: Business Wire) “I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of
Egyptian Singer Becomes First Woman to Perform Before a Mixed Crowd in Saudi Arabia26.4.2018 17:55 | Pressemelding
History was made in Saudi Arabia on Wednesday as a female singer performed before a mixed audience for the first time in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006471/en/ Egypt’s National Arab Music Ensemble of the Egyptian Opera House debuted in Saudi Arabia with the singer Nihad Fathy performing before a 2,500-strong audience in Riyadh. This is the first time a woman singer performed on stage in the Kingdom before a mixed crowd. (Photo courtesy of GCA Saudi Arabia.) Egypt’s National Arab Music Ensemble (AME) of the Egyptian Opera House debuted in the Kingdom with the singer Nihad Fathy performing before a 2,500-strong audience at King Fahad Cultural Center in Riyadh. The crowd broke into a rapturous applause as she took to the stage. The Egyptian Opera House ensemble, which was led by famous conductor Moustafa Helmy, comprised 45 male and female musicians and singers, including the star singers A
Pharnext Appoints Amit Kohli as Chief Operating Officer26.4.2018 16:00 | Pressemelding
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Amit Kohli, a senior healthcare industry executive, as Chief Operating Officer (COO). Mr. Kohli is responsible for leading Pharnext’s corporate strategy and operations. “Amit is a seasoned leader with over 20 years’ experience in the healthcare industry, and we are thrilled he is joining Pharnext,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are deeply impressed with Amit’s results-oriented track record, and his ability to drive business strategy and operations across the pharma, medtech and clinical diagnostics sectors. We believe Pharnext will greatly benefit from his extensive cross-functional leadership experience especially as our first-in-class orphan drug, PXT3003, for the
Leading Marine Container Leasing Management Team Launches Global Container International26.4.2018 15:33 | Pressemelding
Jeffrey Gannon and Adrian Dunner, in partnership with investment vehicles managed by Wafra Inc., today announced the formation of Global Container International LLC (“Global”), a new marine container leasing platform headquartered in Boston, Massachusetts and with representation in Hong Kong, Shanghai, Singapore, Antwerp, Taipei, and Seoul. With a near-term goal of building a fleet of 1 million TEU (twenty-foot equivalent units), Global is positioned to provide its customers a reliable alternative source of capital and containers for lease. Jeffrey Gannon serves as Chief Executive Officer of Global, and Adrian Dunner serves as Chief Operating Officer. Together, they offer clients a combined 50 years of experience backed by successful track records in the container leasing industry. Global will invest in marine containers and related equipment made available for lease under a wide range of structures to meet customer needs. Investments will include new build containers, portfolio purcha